Pulmatrix, Inc. PULM

PULM Company Overview

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory and pulmonary diseases. The company operates within the biotechnology and specialty pharmaceutical industries, with a strategic emphasis on drug delivery technologies designed to improve localized treatment in the lungs while potentially reducing systemic side effects. Its core platform technology, commonly referred to as iSPERSE, is engineered to create dry powder formulations intended for efficient pulmonary delivery of therapeutic agents.

The company’s primary business activities have centered on advancing inhaled therapeutics for conditions such as chronic obstructive pulmonary disease (COPD), asthma, and rare pulmonary disorders. Pulmatrix has historically pursued development programs through a combination of internal research, licensing arrangements, and strategic collaborations with pharmaceutical partners. The company was founded in 2003 and became publicly traded through a reverse merger transaction completed in 2015. Public filings and company disclosures indicate that Pulmatrix’s strategic positioning has relied heavily on its proprietary inhalation technology platform and partnership-oriented development model.